Anhui Wanbang Pharmaceutical TechnologyLtd Third Quarter 2024 Earnings: EPS: CN¥0.34 (vs CN¥0.47 in 3Q 2023)

Simply Wall St · 10/26 01:13

Anhui Wanbang Pharmaceutical TechnologyLtd (SZSE:301520) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥106.1m (up 40% from 3Q 2023).
  • Net income: CN¥22.8m (down 3.1% from 3Q 2023).
  • Profit margin: 22% (down from 31% in 3Q 2023).
  • EPS: CN¥0.34 (down from CN¥0.47 in 3Q 2023).
earnings-and-revenue-history
SZSE:301520 Earnings and Revenue History October 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Anhui Wanbang Pharmaceutical TechnologyLtd shares are up 7.0% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Anhui Wanbang Pharmaceutical TechnologyLtd (1 shouldn't be ignored!) that you should be aware of.